Beatrice Pennati

Mrs. Beatrice Pennati

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 June 2021 in International Journal of Infectious Diseases
Verified
Journal Article
Open access
BBBianca Bruzzone
Bianca Bruzzone
VPVanessa De Pace
Vanessa De Pace
PCPatrizia Caligiuri
Patrizia Caligiuri
VRValentina Ricucci
Valentina Ricucci
GGGiulia Guarona
Giulia Guarona
GIGiancarlo Icardi
Giancarlo Icardi
The availability of accurate and rapid diagnostic tools for COVID-19 is essential for tackling the ongoing pandemic. Our study aimed to quantify the performance of available antigen-detecting rapid diagnostic tests (Ag-RDTs) in a real-world hospital setting. In this retrospective analysis, the diagnostic performance of 7 Ag-RDTs was compared with real-time reverse transcription quantitative polymerase chain reaction assay in terms of sensitivity, specificity and expected predictive values. A total of 321 matched Ag-RDTreal-time reverse transcription quantitative polymerase chain reaction samples were analyzed retrospectively. The overall sensitivity and specificity of the Ag-RDTs was 78.7% and 100%, respectively. However, a wide range of sensitivity estimates by brand (66.0%–93.8%) and cycle threshold (Ct) cut-off values (Ct <25: 96.2%; Ct 30–35: 31.1%) was observed. The optimal Ct cut-off value that maximized sensitivity was 29. The routine use of Ag-RDTs may be convenient in moderate-to-high intensity settings when high volumes of specimens are tested every day. However, the diagnostic performance of the commercially available tests may differ substantially.

1 September 2021 in Journal of Virological Methods
Verified
Journal Article
Closed access
AOAndrea Orsi
Andrea Orsi
BPBeatrice Pennati
Beatrice Pennati
BBBianca Bruzzone
Bianca Bruzzone
VRValentina Ricucci
Valentina Ricucci
DFDiego Ferone
Diego Ferone
GIGiancarlo Icardi
Giancarlo Icardi

6 August 2023 in Skin Research and Technology
Verified
Journal Article
Open access
LCLuigi Coricciati
Luigi Coricciati
MGMaddalena Gabellone
Maddalena Gabellone
PDPantalea Delle Donne
Pantalea Delle Donne
BPBeatrice Pennati
Beatrice Pennati
TZTiziano Zingoni
Tiziano Zingoni
Background: Melasma is an acquired skin problem. It characterises sun‐exposed areas, particularly on the face, with irregular borders and bilateral distribution. With this study, we want to strengthen the scientific literature regarding the use of a 675‐nm laser device for the treatment of women and men with facial melasma pigmentary and vascular symptoms. Materials and methods: Eighteen patients were treated for facial melasma. A total of three sessions at 30‐day intervals were performed with a 675‐nm laser device. A five‐point Global Aesthetic Improvement Scale was used to separately assess the improvement of the patient's skin 3 months after the last treatment (T1) compared to baseline (T0). The pain during treatment was measured using a Visual Analog Scale of 10 points. The non‐ablative laser system used emits red light with a wavelength of 675 nm through a 13 × 13 mm scanning system. Results: At T 1 , a consistent improvement in the pigmentary and vascular components was visible. This is always combined with a considerable reduction in vascular expression. Conclusion: Our research shows that individuals with Fitzpatrick phototypes II to III can treat facial melasma with the 675‐nm laser source system without risk. Due to its interaction with melanin, collagen and haemoglobin chromophores, as well as its excellent capacity to penetrate tissues with less heating, this system is promising in the treatment of pigmentary and vascular illnesses such as melasma. The great success of the technology we used came from the reduced levels of inflammation produced after the treatments and the low energy level implied.

3 May 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Maurizio FilippiniMaurizio Filippini
Maurizio Filippini
NBNicoletta Biordi
Nicoletta Biordi
ACAntonella Curcio
Antonella Curcio
ACAlessandra Comito
Alessandra Comito
BPBeatrice Pennati
Beatrice Pennati
MFMiriam Farinelli
Miriam Farinelli
Background and objectives: Involuntary loss of urine owed to dysfunction of the detrusor muscle or muscles of the pelvic floor is known as urinary incontinence (UI). In this study, ultrasound monitoring was employed for the first time to measure the usefulness and safety of electromagnetic stimulation for women with Stress or Urge UI. Materials and Methods: A total of 62 women were enrolled, with a mean age of 55.1 (±14.5); 60% of them were menopausal and presented with urinary incontinence (UI). Eight validated questionnaires were used to evaluate Stress UI, prolapse, overactive bladder urge, faecal incontinence, and quality of life, and the whole study population was tested with ultrasounds at the beginning and at the end of the treatment cycle. The device used was a non-invasive electromagnetic therapeutic system composed of a main unit and an adjustable chair applicator shaped for deep pelvic floor area stimulation. Results: Ultrasound measurements and validated questionnaires revealed a consistent and statistically significant (p < 0.01) improvement of the mean scores when pre- and post-treatment data were considered. Conclusions: Study results showed that the proposed treatment strategy led to a significant improvement in Pelvic Floor Muscle (PFM) tone and strength in patients with UI and pelvic floor disorders, without discomfort or side effects. The demonstration was qualitatively carried out with validated questionnaires and quantitatively with ultrasounds exams. Thus, the “chair” device we used represents valuable and effective support that could be widely employed in the gynaecological field for patients affected by different pathologies.

2 August 2023 in Skin Research and Technology
Verified
Journal Article
Open access
CGCannarozzo Giovanni
Cannarozzo Giovanni
BPBeatrice Pennati
Beatrice Pennati
ZTZingoni Tiziano
Zingoni Tiziano
Introduction: The Flash‐lamp pulsed dye laser (FPDL) is nowadays considered the most precise laser currently on the market for treating superficial vascular lesions. In this study, we gathered data from 10 years of experience regarding dye laser treatment of patients presenting vascular malformations such as telangiectasia, rhinophyma, port‐wine stain, cherry and spider angioma and vascular tumours. Methods: Subjects were enrolled from 2013 to 2023 based on the vascular anomalies they presented. They underwent different treatment sessions with the FPDL device. Results: The age‐range distribution by vascular anomaly confirmed that haemangiomas are typical in children while rhinophyma is a condition very common in older adults. A difference in sex distribution showed that pathologies such as telangiectasias typically affect women whereas rhinophyma is more frequent in men. Most of the treatments interested the face area but no permanent side effects were registered. Conclusions: Our 10 years of experience with FPDL demonstrated good results in a wide range of applications for the treatment of different vascular anomalies. The absence of long‐term side effects and bearable pain during the treatment makes it a valuable solution for the resolution of benign tumours also in very young patients.

31 July 2023 in Medicina
Verified
Journal Article
Open access
PDF file
Domenico PiccoloDomenico Piccolo
Domenico Piccolo
MMMohammed Hussein Mutlag
Mohammed Hussein Mutlag
LPLaura Pieri
Laura Pieri
BPBeatrice Pennati
Beatrice Pennati
CCClaudio Conforti
Claudio Conforti
PBPaolo Bonan
Paolo Bonan
Background: Dermal fillers for soft tissue for the treatment of face sagging, volume loss, and wrinkles have become popular among patients of all ages and ethnicities, and their use is becoming increasingly widespread. Aim: the goal of this study was to evaluate the effectiveness and safety of a micro-pulsed, 1444 nm Nd:YAG laser on dermal filler complications, in particular on granuloma management. Methods: A subcutaneous, 1444 nm Nd:YAG laser was used on five female patients (range age 52–68 years) with hyaluronic filler granulomas located on the face (two on the cheek area and three on the lips); three patients had self-injected the filler, buying it online. Before and after the therapy, the patients received a skin ultrasound to determine the form and location of the granulomas and to determine if there had been a full or partial resolution. During this study, all possible adverse effects at the treatment site were monitored. The 5-point Global Aesthetic Improvement Scale (GAIS) (0 point—no change; 1 point—25%, mild improvement; 2 points—50%, moderate improvement; 3 points—75%, good improvement; 4 points—100%, excellent improvement) was recorded at a 3-month follow-up. Results: good results were obtained in the treatment of filler granulomas with the intralesional 1444 nm laser, even if just a single treatment was performed (one intervention was effective for curing granulomas up to 5 mm in diameter). Three patients were satisfied with excellent improvement, and two patients experienced good improvement. The results are functional and aesthetically satisfying, as shown by photographic assessment. At the last follow-up, the granuloma had reduced or completely disappeared in all cases, and no infections, burns, scarring or fibrosis, episodes of severe bleeding, or other serious adverse effects had been reported. All subjects tolerated the post-treatment period well. Conclusions: Our findings showed that granuloma treatment with an intralesional 1444 nm Nd:YAG laser is a minimally invasive, easy, fast, efficient, and low-risk procedure.